New York Life Investment Management LLC Makes New Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

New York Life Investment Management LLC bought a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,656 shares of the biopharmaceutical company’s stock, valued at approximately $763,000.

A number of other hedge funds also recently bought and sold shares of ITCI. Xponance Inc. raised its stake in shares of Intra-Cellular Therapies by 3.0% during the 4th quarter. Xponance Inc. now owns 5,676 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 163 shares during the period. Regal Investment Advisors LLC raised its position in shares of Intra-Cellular Therapies by 1.4% during the 3rd quarter. Regal Investment Advisors LLC now owns 13,610 shares of the biopharmaceutical company’s stock worth $709,000 after purchasing an additional 186 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its stake in Intra-Cellular Therapies by 0.8% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 26,796 shares of the biopharmaceutical company’s stock valued at $1,396,000 after buying an additional 200 shares in the last quarter. Bailard Inc. boosted its holdings in Intra-Cellular Therapies by 1.2% in the 4th quarter. Bailard Inc. now owns 17,080 shares of the biopharmaceutical company’s stock worth $1,223,000 after buying an additional 200 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in Intra-Cellular Therapies by 85.7% in the 4th quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 239 shares during the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Sharon Mates sold 20,565 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $65.21, for a total value of $1,341,043.65. Following the sale, the chief executive officer now directly owns 1,050,309 shares in the company, valued at approximately $68,490,649.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Sharon Mates sold 20,565 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $65.21, for a total value of $1,341,043.65. Following the transaction, the chief executive officer now owns 1,050,309 shares in the company, valued at approximately $68,490,649.89. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Lawrence J. Hineline sold 10,121 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $65.96, for a total value of $667,581.16. The disclosure for this sale can be found here. Insiders sold 168,487 shares of company stock worth $11,364,950 in the last 90 days. Corporate insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Trading Down 5.9 %

Shares of NASDAQ ITCI opened at $67.00 on Thursday. Intra-Cellular Therapies, Inc. has a 12-month low of $45.50 and a 12-month high of $84.89. The stock has a market cap of $6.49 billion, a P/E ratio of -45.89 and a beta of 1.01. The business’s fifty day simple moving average is $69.03 and its 200-day simple moving average is $65.86.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The business had revenue of $144.90 million during the quarter, compared to analysts’ expectations of $141.41 million. During the same quarter last year, the business posted ($0.46) EPS. The business’s quarterly revenue was up 52.0% compared to the same quarter last year. On average, equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. TD Cowen raised their target price on Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Bank of America lifted their target price on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Royal Bank of Canada reiterated an “outperform” rating and issued a $86.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. The Goldman Sachs Group boosted their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 17th. Finally, Mizuho increased their price objective on shares of Intra-Cellular Therapies from $82.00 to $96.00 and gave the company a “buy” rating in a report on Monday, April 22nd. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Intra-Cellular Therapies presently has an average rating of “Moderate Buy” and a consensus price target of $90.17.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.